 | ||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
| ||
2007 – Licensed CLIP technology from University of Colorado with V-Clip Pharmaceuticals • may explain mechanism of action and conclusively identify active components • may accelerate and allow dose optimization to be completed • now completing studies to confirm CLIP-TNP connection
2006 – Completed double-blind, placebo-controlled study of VGV-1 (South African) • 137-patient study designated “Phase III” by South African Medicines Control Council • No apparent toxicities or significant adverse events related to drug observed • 22% showed significant decrease in HIV viral load 100 days after treatment. Click here for a sample chart: Percent_Responders.PDF • Stronger results in later-stage, sicker patients – consistent with prior studies. Click here for a sample chart: CD4_Responders.PDF
2003 - Conducted 4th prospective study of VGV-1 (China) • No apparent toxicities observed • Decrease in HIV viral load observed • Study focused on late-stage patients who had never received antiretroviral combination therapy previously
1999 - Conducted 4th prospective study of VGV-1 (Mexico) • No apparent toxicities observed • Decrease in HIV viral load observed • Study focused on late –stage patients on failing antiretroviral combination therapies (“salvage therapy”)
1997 - Completed 3rd prospective study of VGV-1 (Bulgaria) • No apparent toxicities observed • Decrease in HIV viral load observed
1996 - Completed 2nd prospective study of VGV-1 (Mexico) • No apparent toxicities observed • Decrease in HIV viral load observed • Study included many late-stage patients
1995 - Completed small prospective human trial of VGV-1 (Bulgaria) • No apparent toxicities • Apparently improved clinical condition
1995 - Company founded in California by Haig Keledjian, Dr. Harry Zhabilov, and Hampar Karageozian
1992 - Haig Keledjian and Dr. Harry Zhabilov pursue thymus nuclear protein (“TNP”) as means of early-detection of HIV and cancer. • additional study revealed TNP’s apparent effect on HIV /AIDS patients when suspended in adjuvant: “VGV-1”
|
|
|
|
Home | About Us | Our Team | Scientific Advisory Board | Discovery Vision | Immune-Based Therapies | TNP | Development | VGV-1 History | Product Timeline | Clinical Trials Press Releases | Media Kits | Media Inquiries | News Subscription Service Investor Contacts | Email Alerts | Fact Sheet | Contact Us | SEC Filings Glossary | Stock Information | Corporate Governance & Board of Directors University of Colorado License | Careers |
|
|
 |
|
|
